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monitored further, using a larger sample size in a subsequent
study. 
The authors gratefully acknowledge that this research was
supported by a grant from the Health Systems Trust.
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Objectives. To record the number of haemophiliacs aged 0 - 18
years in the Western Cape (WC), what event led to the
diagnosis, the level of clotting factor, treatment, functional
status of their joints and impact of the disease on the family.
Design. A prospective study of patients registered with the
South African National Haemophilia Registry and new
patients, utilising the patients’ paediatricians, hospital
records, patient and guardian interviews, physical
examination and provincial nurse haemophilia co-ordinators.
Setting. Haemophilia care centres at the three WC academic
hospitals, regional hospitals and homes of patients. Two
elective medical students, MHH and JJH, collected the
information.
Subjects. All boys with confirmed haemophilia A or B in the
WC.
Outcome measures. Events that led to diagnosis, degree of
haemophilia, use of clotting factor, functional status, and
effect on family.
Results. Of 78 patients (59 haemophilia A, 19 haemophilia B)
identified, 49 could be studied. Forty-three per cent had
severe, 29% moderate and 22% mild disease (6% unknown).
Family history was present in 49%, but led to diagnosis in
only 12%. The most common first symptoms were
subcutaneous and mucosal bleeding. Delay in diagnosis
varied from 0 to 9 months. Twenty-nine per cent of guardians
were suspected of child abuse. RSA produced clotting factor
was used ‘on demand’ in 73% of patients, for periodic
prophylaxis in 20% and as continuous prophylaxis in 7%.
Joints were functionally restricted in 43% of patients. The
majority of guardians (59%) said the disease had a major
impact on the family. 
Conclusions. The diagnosis of haemophilia in children with a
positive family history was often delayed. Haemophilia
causes significant morbidity in our patients and their families.
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Haemophilia A and B are recessive X-linked genetic diseases.
In haemophilia A there is deficiency of factor VIII (FVIII) and
in haemophilia B of factor IX (FIX), resulting in a clotting
disorder. Haemophilia occurs in approximately 20/100 000
male newborns in all ethnic groups, of whom 80 - 85% have
haemophilia A and 10 - 15% haemophilia B.1 Classification of
severity is based on the patient’s blood level of FVIII or FIX. In
the severe form the level of plasma-clotting factor is < 1.0%, in
the moderate form 1.0 - 4.0%, and in the mild form 5.0 - 25.0%
of normal.2,3
Patients with severe haemophilia develop spontaneous joint
and muscle bleeds. Without adequate treatment this may result
in chronic arthropathy. In patients with moderate haemophilia
bleeds usually result from minor trauma. Patients with mild
haemophilia usually present with prolonged bleeding after
trauma or operations.4
Haemophilia can cause severe disability and a reduced life
expectancy. After effective replacement therapy with clotting
factors was introduced in 1960, the complications of
haemophilia decreased in adequately treated patients. At first
pooled factor concentrates (i.e. using a pool of donors) were
used for the treatment of acute bleeding episodes. Later
prophylactic treatment with these concentrates was used to
prevent disability and increase life expectancy. Unfortunately
viral diseases such as hepatitis B, hepatitis C and HIV have
been transmitted to patients, especially in those treated with
concentrates made from a large pool of donors. To prevent
these possible complications, recombinant DNA-produced
FVIII and FIX concentrates are used preferentially if affordable
and available.2
Early diagnosis and adequate treatment are of utmost
importance in preventing severe disability and morbidity. Early
diagnosis can be achieved by focusing on early bleeding events
and the family history.4 One-third of all patients have
haemophilia as a result of a spontaneous genetic mutation, and
are considered sporadic. In some cases designated as sporadic,
the mother may be unaware of the fact that she is a carrier.2
Subcutaneous rather than joint or muscle bleeding is the most
important initial presenting symptom in haemophilia.4
Unawareness of the clinical signs and limited laboratory
facilities may add to a delay in diagnosis in developing
countries.5
The Haemophilia Care Centres (HCCs) for children in the
Western Cape (WC) are located at the Tygerberg Children’s
Hospital, Red Cross Children’s Hospital and Groote Schuur
Hospital, all public tertiary care hospitals. The South African
national haemophilia registry listed 53 children with
haemophilia A and 20 with haemophilia B aged 0 - 18 years,
resident in the WC, on 28 February 2002. The recorded
incidence of haemophilia A was 7/100 000 and that of
haemophilia B 1.1/40 000 male newborns in the WC 
(C D Karabus — personal communication). In the WC patients
are routinely treated with either intermediate-purity small-pool
(heat-treated) concentrate produced by the WC Blood
Transfusion Service, or with intermediate-purity large-pool
concentrate (solvent detergent-treated) produced by the Natal
Bioproducts Institute. These non-profit organisations produce
approximately 18 million IU of FVIII per annum, which
represents about 12 000 IU per South African patient per year,
at a cost of approximately R1.60 per IU of FVIII.5,6 These locally
produced plasma products have no significant risk of
transmitting transfusion-transmitted virus (TTV), although
infection with B19 parvovirus may occur.7 Mean use of FVIII
was 20 000 IU per patient, and that of F1X 6 000 IU per patient
in the WC for the year 1 October 2000 - 31 September 2001 
(CD Karabus — personal communication). Three kinds of
treatment protocols are used in the WC.  The majority of
patients receive clotting factor ‘on demand’ after a bleed. Some
patients with recurrent severe bleeds in a joint are given
clotting factor three times a week as ‘periodic prophylaxis’
until the joint has improved, and a few patients receive
‘continuous prophylaxis’ with clotting factor from shortly after
birth. 
Objectives
Objectives of the study were to identify all children with
haemophilia A and B aged 0 - 18 years in the WC and to record
how the diagnosis had been made, the severity of disease, the
treatment used and the functional status of the joints. Impact of
the disease on the family was also investigated.
Methods
This descriptive, cross-sectional study was performed between
28 January 2002 and 30 April 2002 as a research project by two
elective students (MHH and JJH). Patients’ clinical data,
addresses and telephone numbers were obtained by reviewing
patient records at the three HCCs in the Cape metropole, and
at the regional hospitals of the WC. The event that led to the
first medical consultation, the age of the child at that time and
the age when the diagnosis was confirmed, were recorded. 
Guardians were asked if they had been suspected of abusing
or molesting their child. The type and severity of haemophilia,
number of joint bleeds in the past 12 months and the frequency
of therapy during that 12-month period were recorded. The
status of the patients’ joints was classified as ‘functionally
limited’ if the normal range of movement was decreased in one
or more joints. 
The socioeconomic status of the family was assessed, in part
by determining the employment status of the guardian(s), and
by the availability of private medical insurance. Guardians
were asked if they had made minor or major changes to the
education (and upbringing) of the child after they had learnt of
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the diagnosis, and whether or not the disease had impacted
significantly on their family life. The questionnaires were
conducted at home, at the hospital or at the guardian’s
workplace by MHH and JJH. The presence of a family history
was determined. If there were two affected brothers in a family
where the mother had a negative family history, the first boy
was included in the group with a negative, and the second boy
in the group with a positive family history. Informed consent
was obtained from all guardians and the study was approved
by the Ethical and Research Review Committee of the Faculty
of Health Sciences at Stellenbosch University, South Africa.
Results
Study population
We identified 59 boys with haemophilia A and 19 with
haemophilia B (total 78) aged 0 - 18 years in the WC. We
studied 49 children (63% of the total), 37 with haemophilia A
and 12 with haemophilia B. The remaining 29 patients were not
studied because it had not been possible to arrange an
interview with the guardian or a home visit in the time
available. Twenty-one patients (43%) had severe, 14 (29%)
moderate and 11 (22%) mild haemophilia. The severity of 3
patients (6%) was unknown. 
Diagnosis
A positive family history was obtained in 24 patients (49%), of
whom 8 had severe, 7 moderate 8 mild disease and 3 disease of
unknown severity. The mean delay between the first medical
consultation and the time of diagnosis was 2 months (range 
0 - 9 months) in severely affected patients, 0.5 month (range 
0 - 1.5 months) in moderately affected patients, and 2 months
(range 0 - 8 months) in mildly affected patients. The mean age
at diagnosis was 9 months (range 1.5 - 22 months, median 11.8
months) in severely affected patients, 11 months (range 0.5 - 33
months, median 16.8 months) in moderately affected patients,
and 21 months (range 1 - 48 months, median 24.5 months) in
mildly affected patients.
The most common symptoms that led to the diagnosis of
haemophilia were subcutaneous and mucosal bleeds (45% and
15% respectively). Twelve per cent of patients were diagnosed
after a blood test because of a positive family history. Events
that led to the diagnosis differed according to the severity of
disease. The most common events leading to diagnosis were
subcutaneous haematomas (51%) and iatrogenic causes (14%)
in severely affected patients, a blood test because of a positive
family history (30%) and subcutaneous bleeds (21%) in
moderately affected patients, and subcutaneous bleeds (64%)
and mucosal bleeds (18%) in mildly affected patients (Table I).
Guardians had been suspected of child abuse in 14 cases (29%).
Bruises or bleeding at immunisation sites had been observed in
14 patients (29%).
Treatment and clinical status
Of 36 patients treated ‘on demand’, 30 (83%) had suffered one
or more joint bleeds in the preceding 12 months and 17 (47%)
had one or more functionally restricted joints. Eight of 10
patients (80%) receiving ‘periodic prophylactic treatment’ had
suffered one or more joint bleeds, and 2 (20%) had one or more
functionally restricted joints. Continuous prophylactic
treatment was given to 3 patients, 1 of whom had experienced
a number of joint bleeds and 2 of whom had functionally
restricted joints.
Impact on the family
Twenty-nine female guardians (59%) were gainfully employed,
18 (37%) were not, and in 2 (4%) the employment status was
unknown. Thirty-three (68%) of the male guardians were
gainfully employed, 5 (10%) were not and in 11 cases (22%) the
father’s work status was not applicable (mother a single
parent). Only 14 guardians (29%) had some form of medical
insurance. Although guardians who are medically insured are
billed for service, and poor parents are requested to pay a
nominal fee whenever they attend a health care facility,
treatment was provided free of charge to every patient who
could not afford to pay for hospital treatment.
Twenty-three sets of guardians (47%) made major changes in
the household, such as resigning from employment to care for
the child, preventing the child from participating in sport and
confining the child to the home. Thirteen of 24 guardians (54%)
with a positive family history and 16 of 25 (64%) with a
negative family history said that haemophilia had had a major
impact on their family life. The remainder said there was little
or no impact on their family life. 
Discussion
We identified 78 children with haemophilia in the WC,
including 5 children who were not listed in the national
registry. These 5 children were known at regional hospitals, but
the registry had not been notified and they had not been
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Table I. Factors that led to the diagnosis in patients with severe,
moderate and mild haemophilia*
Severe Moderate Mild 
Factors leading to diagnosis % (N) % (N) % (N)
Subcutaneous haematomas 51 (11) 21 (3) 64 (7)
Iatrogenic causes 14 (3) 7 (1) 9 (1)
Mucosal bleeds 10 (2) 21 (3) 18 (2)
Family history 10 (2) 30 (4) 0
Intra/extracranial bleeds 10 (2) 0 0
Joint or muscle bleeds 5 (1) 21 (3) 9 (1)
*Severity unknown in 3 patients. 
Original Articles  11/5/03  8:24 AM  Page 795
796
October 2003, Vol. 93, No. 10  SAMJ
ORIGINAL ARTICLES
referred to a HCC. Internationally, haemophilia A is four times
as common as haemophilia B.1 In the WC it is three times as
common, indicating under-diagnosis of haemophilia A.5 The
categorisation of severity of haemophilia depends on an assay
of the blood level of the clotting factor and may be influenced
by laboratory techniques. We accepted the different hospital
laboratory reports as accurate for the purposes of this study. 
We were unable to find a clear definition of a ‘positive family
history’ in the literature. In the case of two brothers with
haemophilia the oldest may have a negative family history, but
the younger will have a positive family history by virtue of his
affected brother. For this reason we did not compare our family
history incidence rate with that of the literature. It is known
from the literature that about 50 - 60% of mothers are known
carriers.
The mean age at diagnosis for severe haemophilia patients
was 9 months, which is similar to the age recorded by Ljung et
al.,3 while patients with moderate haemophilia were diagnosed
earlier (mean age 11 months) compared with 21 months in the
study by Ljung et al.3
Clinical presentation in the WC patients was similar to that
recorded by Pollmann et al.8 In that study 47% of severe
haemophiliacs presented with subcutaneous haematomas
compared with 52% in this study. In Pollmann’s study 24% of
severe haemophiliacs were diagnosed because of a positive
family history, compared with only 10% in this study, despite
the fact that 38% of patients in the WC had a positive family
history. Interestingly, 14% of our patients were diagnosed after
iatrogenic trauma, mainly immunisation. In moderately severe
haemophiliacs a family history led to the diagnosis in 4 of 7
children, and in 0 of 8 children with mild haemophilia. Poor
counselling may explain why families are unaware of a family
history and the role of heredity, which in turn may explain
why children with a positive family history were not
commonly diagnosed shortly after birth.4 Unfamiliarity on the
part of the attending physician or nursing sister with regard to
the clinical presentation of haemophilia may also contribute to
delay in the diagnosis.4 Wrongfully accusing guardians of child
abuse is disconcerting, and a diagnosis of a bleeding disorder
should always be considered first when children are
investigated for non-accidental injuries.
The majority (73%) of children in the WC received clotting
factor on demand, that is only after a bleed. Eighty-three per
cent of this group had experienced joint bleeds in the preceding
year, and almost half of the patients had functionally restricted
joints. Children who received periodic prophylactic treatment
because of repeated serious joint bleeds had a much lower rate
of non-functional joints (20%), but 80% had still experienced
joint bleeds in the preceding year.  Periodic prophylaxis
therefore appears to be helpful in maintaining joint function,
but not in preventing bleeds. Continuous prophylaxis, which is
the accepted best treatment, was only used in 3 patients,
making comments on the possible benefit inappropriate. The
South African national annual production of FVIII is
approximately 12 000 IU per patient per year. This fact, and the
high cost of imported products, cannot support a local
continuous prophylaxis programme for all severe
haemophiliacs. Prophylactic therapy with recombinant FVIII
from birth onwards largely prevents arthropathy, and is given
to 80% of children with severe haemophilia in the
Netherlands.9,10 This is currently unaffordable in the public
sector in South Africa.
The extra demands on parents and children in these families
are clear, and guardians need active support to raise their child
with the minimum amount of physical and emotional damage,
and to assist the child to achieve the best possible educational
level. Family income is often inadequate because a guardian
may have to give up his/her work to look after the child. The
national budget for 2003 has fortunately increased the age up
to which children will qualify for financial support from the
Ministry of Social Affairs. Guardians need to be fully informed
on all aspects of the disease, and be encouraged to use the
expertise of the nearest HCC. Two specially trained nursing
sisters have been appointed in the WC to counsel and assist
patients and parents, to train them in home therapy and to
promote optimal therapy at the HCC. The principle of optimal
treatment is to diagnose and plan treatment at an HCC, and to
involve the local public health care facility at community level
in the day-to-day management.
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